OT mobile menu

Search form


AACR 2015

AACR 2015

A new strategy in the treatment of estrogen receptor (ER) breast cancer may be in the form of an ER degrader. Like the antiestrogen tamoxifen (Soltamox, Nolvadex), this treatment also prevents estrogen from stimulating tumor growth.

A specific genetic signature may predict how solid tumor cancer patients respond to the immunotherapeutic drug entolimod in terms of tumor shrinkage as well as potentials side effects from the drug.

An important discovery regarding the bladder cancer genome was announced during the American Association for Cancer Research (AACR) meeting in Philadelphia, held April 18-22, 2015.

MM-302 showed encouraging efficacy results and a manageable safety profile in heavily pretreated HER2-positive metastatic breast cancer patients.

Treatment with nivolumab and ipilimumab in patients with advanced melanoma produced significantly higher rates of response and progression-free survival compared with ipilimumab alone.

Treatment with pembrolizumab resulted in an estimated 6-month PFS rate that was almost double that of treatment with ipilimumab in advanced melanoma patients.

Subscribe to AACR 2015 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.